Marco Donia, Professor at CCIT-DK, shared by Marie Weitemeyer, PhD Fellow at Copenhagen University Hospital, on LinkedIn.
“A small but real OS advantage in patients with resected stage III melanoma, treated with adjuvant anti-PD1
(note however all the limitations of our new real-world study)”
Quoting Marie Weitemeyer:
“Does adjuvant anti-PD-1 improve survival in stage III melanoma in real-world clinical practice?
Using nationwide Danish data with 5 years of follow-up, we found:
- No clear population-level survival benefit after the introduction of adjuvant anti-PD-1.
- Higher OS among treated patients at 5 years in matched analyses (80.3% vs. 71.7%; HR 0.67, 95% CI 0.47–0.95), while melanoma-specific mortality remained inconclusive (16.6% vs. 20.8%; HR 0.77, 95% CI 0.52–1.14).
- Interpret with caution: ower other-cause mortality among treated patients despite matching suggests residual confounding (healthy-user bias).
Take home:
With the treatment landscape rapidly changing, our findings support the importance of carefully individualized adjuvant treatment decisions.
And a bit of a hobbyhorse of mine: this study is a good reminder of the value of competing-risk analyses in RWE. Looking beyond OS can add important context and nuance when interpreting apparent treatment effects.
A huge thank you to all co-authors, and to everyone contributing to the Danish Melanoma Database and the Danish Metastatic Melanoma Database (DAMMED), and to the patients who donated the use of their data.”
Title: Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma
Authors: Marie B. Weitemeyer, Neel M. Helvind, Shawez Khan, Pernille Bidstrup, Karina D. Steffensen, Adam Andrzej Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marco Donia, Lisbet R. Hölmich, Eva Ellebaek
You can aslo read: PIVOTAL Trial: Neoadjuvant Intralesional Immunotherapy in Melanoma
